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Abstract
Background: Diarrhea causes an estimated 2.5 million child deaths in developing countries each
year, 35% of which are due to acute diarrhea. Zinc and copper stores in the body are known to be
depleted during acute diarrhea. Our objectives were to evaluate the efficacy of zinc and copper
supplementation when given with standard treatment to children with acute watery or bloody
diarrhea.
Methods: We conducted a double-blind randomized controlled clinical trial in the Department of
Pediatrics at Indira Gandhi Government Medical College Nagpur, India. Eight hundred and eight
children aged 6 months to 59 months with acute diarrhea were individually randomized to placebo
(Pl), zinc (Zn) only, and zinc and copper (Zn+Cu) together with standard treatment for acute
diarrhea.
Results: The mean duration of diarrhea from enrolment and the mean stool weight during hospital
stay were 63.7 hours and 940 grams, respectively, and there were no significant differences in the
adjusted means across treatment groups. Similarly, the adjusted means of the amount of oral
rehydration solution or intravenous fluids used, the proportion of participants with diarrhea more
than 7 days from onset, and the severity of diarrhea indicated by more than three episodes of some
dehydration or any episode of severe dehydration after enrolment, did not differ across the three
groups.
Conclusion: The expected beneficial effects of zinc supplementation for acute diarrhea were not
observed. Therapeutic Zn or Zn and Cu supplementation may not have a universal beneficial
impact on the duration of acute diarrhea in children.
Trial registration: The study was registered as an International Standard Randomized Controlled
Trial (ISRCTN85071383).
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Background
Diarrhea causes an estimated 2.5 million child deaths in
developing countries each year, 35% of which are due to
acute diarrhea [1]. The importance of zinc and copper in
the pathophysiology of acute diarrhea is highlighted by
the significantly higher daily fecal losses of these elements
during acute diarrheal episodes than the fecal losses in
unaffected children [2]. Conversely, zinc supplementa-
tion exhibits therapeutic action by facilitating the trans-
port of water and electrolytes across the intestinal mucosa,
preventing villous atrophy and improving overall immu-
nity [3]. A pooled analysis of the impact of zinc supple-
ments added to the treatment regimens for acute diarrhea
has reported a beneficial effect of reduction in the dura-
tion of diarrhea [4]. A recently published Cochrane review
has reported a reduction of the duration of acute diarrhea
in the zinc group by 12 hours, but there was significant
heterogeneity between the trials examined [4,5]. Conse-
quently, the current paradigm favors the use of Zn supple-
mentation for treatment of acute diarrhea in children [6].
The reported efficacy of zinc therapy for acute diarrhea,
although encouraging, needs to be considered in the light
of several caveats. First, the initial pooled analysis
reported a beneficial effect of zinc on duration of diarrhea
but a similar effect on the volume of stools was not
included in this analysis or the subsequent Cochrane
review [4]. Second, additional supplementations in the
form of multivitamins or vitamin A were also adminis-
tered with zinc and placebo in most of the studies
included in these reviews, and it is difficult to ignore the
possibility of synergistic effects of the co-interventions.
Third, the potential beneficial effects of zinc supplemen-
tation across different sub-groups of children with acute
diarrhea based on age, nutritional status or diarrheal eti-
ology are still not established [7,8]. Lastly, community-
based trials are more prone to difficulties with monitor-
ing, compliance and measurement of the trial outcomes
such as stool frequency, volume and duration. Large com-
munity-based, cluster-randomized, double-masked, pla-
cebo-controlled trials of daily prophylactic supplements
of 10 mg of zinc found no significant difference in fre-
quency of diarrhea, duration, all-cause hospitalization
rates or overall mortality, in Nepal, India and Zanzibar [9-
11].
It has been speculated that simultaneous depletion of the
copper stores can affect diarrhea morbidity and mortality
[12], but the preventive or therapeutic role of copper sup-
plementation is still unclear. It is possible that children
supplemented with both zinc and copper experience
greater reductions in the duration of diarrhea. We there-
fore conducted a hospital-based double-blind rand-
omized controlled trial to evaluate the efficacy of zinc and
copper supplementation when given with standard treat-
ment to children with acute watery or bloody diarrhea.
The primary hypothesis of the study was that the children
supplemented with zinc or zinc and copper would experi-
ence a reduction in the duration of diarrhea, the volume
of stool output and the rates of complications, as com-
pared with those receiving placebo.
Methods
This was a double-blind, randomized, placebo-controlled
clinical trial. The eligibility criteria for this trial were all
children aged 6 months to 59 months attending the Indira
Gandhi Government Medical College and Hospital in
Nagpur, India, with more than three unformed stools in
the prior 24 hours; duration of diarrhea up to 72 hours;
and ability to accept oral fluids or feeds. Children who
were severely dehydrated as per the World Health Organ-
ization (WHO) criteria and unable to accept treatment
orally were rehydrated with Ringer's lactate and reviewed
4 hours later for ability to take orally [13]. The children
were screened for eligibility by a trained study physician.
The exclusion criteria were: chronic or severe complicating
illness, known positive HIV status, kwashiorkor, residing
outside a radius of 30 km around the hospital, participat-
ing in another study or already enrolled in this study. The
consent procedure was administered to parents or guardi-
ans of the children and those who gave informed consent
were enrolled and randomized. The Ethics Committee of
Indira Gandhi Government Medical College, Nagpur, and
the Human Research Ethics Committee of the University
of Newcastle, New South Wales, Australia (HREC
Approval No: H-500-0203) approved the study protocol,
and the treatment effects monitoring committee moni-
tored the trial for safety. The trial is registered with Inter-
national Standard Randomized Controlled Trial with the
unique identifier ISRCTN85071383.
Randomization and blinding
Each recruited child was sequentially assigned to one of
the following three treatment arms using a randomization
protocol fixed a priori : placebo (Pl) arm, zinc (Zn) only
arm, and zinc and copper (Zn+Cu) arm. Single-site,
blocked randomization procedure was used for random
allocation with blocks of sizes three, six and nine in equal
proportions to ensure uniform allocation ratio. The treat-
ment allocation sequence was generated off site by an
investigator (HK) not directly involved in the data collec-
tion, using the ClinStat software package [14]. The code
list of the placebo and the treatment groups was secured
and held only by the pharmacist at the Universal Medica-
ments Pvt. Ltd, Nagpur, until initial data analysis was
completed. The bottle packs were sequentially labeled
according to the treatment allocation list and assigned to
patients by the research physician.BMC Medicine 2009, 7:22 http://www.biomedcentral.com/1741-7015/7/22
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Interventions
Brown bottles of Pl, Zn and Zn+Cu supplements were pre-
pared by Universal Medicaments Pvt. Ltd, Nagpur, India.
The contents were checked by two independent laborato-
ries at the beginning of and during the trial. All the bottles
contained a brown-colored syrupy liquid of pH 3 to 4 and
weight 1.2 mg/ml, similar in appearance and taste. The Zn
supplement bottle had zinc sulfate equivalent to 20 mg/5
ml of elemental zinc, and the Zn+Cu supplement bottle
had copper sulfate equivalent to 2 mg/5 ml elemental
copper in addition to zinc in the aforementioned dose.
The therapeutic dose for all participants was 0.5 ml/kg/
day of the syrup (that is, the dose of zinc was 2 mg/kg/day
and of copper was 0.2 mg/kg/day). The dose was repeated
if the patient vomited following administration. The syr-
ups were administered during the hospital stay and con-
tinued after discharge to complete a total duration of 2
weeks from enrolment in the trial. Treatment adherence
was measured by weighing the bottles at enrolment, at
discharge and on the 14th day of follow-up. In hospital,
the patients were monitored for dehydration and fluid
balance was maintained using the WHO standard guide-
lines and oral rehydration solution (ORS) [13]. Briefly,
each child was given approximately 100 ml/kg of ORS
during the first 4 hours by frequent sips using a spoon,
and on-going fecal losses were replaced with the same
solution on a volume-to-volume basis until diarrhea
ceased. Mothers were encouraged to nurse or feed their
children.
Baseline assessment
At enrolment, the study research physician collected infor-
mation from the mother about: age, gender, duration of
illness (fever, vomiting, diarrhea), degree of dehydration,
type of stools, immunization status, existing feeding prac-
tices, maternal education, number of children in the
household, household assets and facilities, water safety,
hand sanitation, intake of anti-diarrheal or antimicrobial
agents, type of rehydration practiced at home, and hemo-
globin concentration (Hemocue method) [13,15]. The
household wealth index, water and hand sanitation scores
were composite indices derived by scoring different fac-
tors that contributed to these indices using principal com-
ponent analysis [16]. Factors assessed for the household
wealth index were ownership of electricity, radio, televi-
sion, refrigerator, bicycle, scooter and land, main material
used for dwelling floor and fuel used for cooking. For the
water safety score the main source of drinking water, water
storage and treatment of drinking water before use were
assessed, and for the hand sanitation score washing of
hands by soap and water, mud, plain water or not washed
before feeding the child and after going to latrine were
assessed.
Nutritional status was assessed by measuring weight and
height using standard methods and calculating weight-
for-age and weight-for-height Z scores using the WHO
2005 Anthro software [17]. Weight was measured to near-
est 100 gm using an electronic scale (Wedderburn Tanita
HD-316). For children aged under 2 years length was
measured in the supine position on a wooden sliding
board; those over 2 years had stature measured using a
height board. Venous blood samples were collected and
immediately centrifuged (3500 rpm or G of 1600 for 15
minutes) in metal-free serum gel tubes (Greiner-Bio-One,
Austria) and transported to the laboratory for serum ferri-
tin (Micro particle Enzyme Immunoassay), serum zinc,
and serum copper estimation using atomic absorption
spectrophotometer (Perkin Elmer Model AA 600 with
Zeeman background correction, and HGA-600 graphite
furnace and an AS- 800 auto sampler were used together
with a zinc/copper hallow cathode lamp).
Monitoring of participants
The patients were monitored for dehydration, vomiting,
complications (electrolyte imbalance, hemolytic uremic
syndrome, septicemia, co-morbidities such as severe ane-
mia, malaria, pneumonia, meningitis, and death), and the
need for unscheduled intravenous (IV) fluids (use of IV
fluids on appearance of severe dehydration despite appro-
priate ORS administration) and its volume (in milliliters)
until discharge. Oral rehydration salts and water were sup-
plied in a container of known volume capacity and the
total amount consumed from start of the study to the ces-
sation of diarrhea was calculated in milliliters. Stool out-
put was measured every 6 hours by placing the child in a
cot with a funnel connected to pre-weighed calibrated
plastic collection jars to estimate stool volume (in millili-
ters) and weight (in grams) by using an electronic scale.
Disposable urine collection bags were used with frequent
changing to ensure that urine was not mixed with stool to
measure urine volume.
After cessation of diarrhea, patients were discharged and
instructed to continue the supplementation at home in
similar doses, and to return to the hospital for a scheduled
follow-up check on the 14th day after discharge, or earlier
if there was repeated onset of vomiting or diarrhea or any
other illness. They were also advised not to administer any
other medication. The weight of syrup bottles was meas-
ured at the start of administration, at discharge and at the
end of 14 days, to assess treatment adherence in hospital
and at home. A second venous blood sample was
obtained at a follow-up visit after the completion of 14
days of treatment for assessment of serum zinc and cop-
per.
A child was discontinued from the study for any of the fol-
lowing reasons: complications such as electrolyte imbal-BMC Medicine 2009, 7:22 http://www.biomedcentral.com/1741-7015/7/22
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ance, azotemia, convulsion, acidosis, congestive heart
failure, hemolytic uremic syndrome, septicemia, loss of
consciousness or death, preventing the child from taking
oral fluids or medications; occurrence of a serious adverse
event; parent or guardian withdrawal of consent; or if the
patient left against medical advice.
Outcome measures
The following primary outcomes were measured: dura-
tion of diarrhea (in hours) from onset and from admis-
sion until cessation of diarrhea (passage of soft/formed or
no stools for two consecutive 8-hour periods), and the
total stool weight in grams during hospitalization. Sec-
ondary outcomes included the amount of ORS and the
amount of IV fluids used, absolute and percentage change
in zinc and copper at day 14 after discharge as compared
with baseline in each patient and their means in each
group, the rate of complications in hospital, and episodes
of any or severe dehydration in hospital.
Sample size calculation
The sample size was calculated on the basis of the hypoth-
esis requiring the largest number of subjects (for example,
15% reduction in estimated mean duration of diarrhea of
93 ± 43 hours based on unpublished data) and assuming
90% power, a Bonferroni-corrected 5% level of signifi-
cance (permitting comparisons of two Zn-containing trial
arms with the placebo arm) and a 2-tailed test. The
required sample size was 234 subjects per group. Allowing
for an expected attrition rate of 15%, the required sample
size was 808.
Statistical analysis
Data was entered each day into pre-programmed Micro-
soft Access software database. Stata 10/IC (Stata Corpora-
tion, College Station, TX) software was used for statistical
analysis. Anthropometric indicators were calculated using
WHO's 2005 Anthro software [17]. Baseline characteris-
tics of the three treatment groups were compared using
chi-square tests for categorical variables and ANOVA (or
the non-parametric equivalent Kruskal-Wallis test) for
continuous variables. Differences between the interven-
tion groups were estimated using multiple regression after
adjusting for baseline covariates such as age, gender, prior
duration of diarrhea, weight for age less than -2 Z -score,
dehydration status, any medication received, water safety,
wealth index, type of stool, serum zinc and serum copper.
Using intention to treat analysis, the unadjusted and
adjusted odds ratio (adjusted for the baseline variables) of
diarrhea longer than 7 days from onset, of complications
in hospital, of more than three episodes of some dehydra-
tion and of severe dehydration experienced in hospital
was estimated using logistic or Poisson regression models.
Cox proportional hazards models were used to estimate
the relative hazards (RH) of cessation of diarrhea in the
three groups and to explore associations between the
same baseline covariates and outcome. The Kaplan-Meier
curves for the cumulative probability of cure from
diarrhea were also plotted for the three groups and the
overall difference in the rates of diarrhea cessation was
examined using the log-rank test.
Role of the funding source
The study sponsor, The Wellcome Trust, played no role in
the design or implementation of the collection, analysis,
or interpretation of data, or in the writing of this report, or
in the decision to submit this paper for publication.
Results
Admission characteristics of participants
A total of 1200 children were screened from August 2003
to October 2006 for eligibility and 808 were randomized
(Figure 1). Each child was followed for 3 months. Imbal-
ance by chance across trial arms was observed in the fol-
lowing baseline characteristics: dehydration status, ORS
received by the child prior to enrolment and serum zinc
(Table 1). The overall mean duration of diarrhea before
enrolment was 35.4 hr and balanced across the groups.
There was no significant difference in nutritional status
and sanitation indicators across the groups. The propor-
tion of children discharged after cessation of diarrhea was
91%, 94% and 95% in the Pl, Zn and Zn+Cu groups
respectively (Figure 1). There were three deaths, two in the
Pl group and one in the Zn group. Based on the results of
the interim analysis, the treatment effects monitoring
committee found no relationship of the deaths to the trial
treatments. Serious adverse events related to the syrups
were not experienced by any child.
Treatment adherence
The proportion of children who completed 14 days of oral
syrup intake in the Pl, Zn and Zn+Cu groups after dis-
charge was 96.8%, 90.3% and 97.7% respectively (Figure
1). Overall, 66.6% children consumed more than 80% of
the prescribed amount of syrup (Table 2). In hospital,
more than 80% of the supplements were observed to be
consumed in 76.6%, 63.7% and 60.3% of the Pl, Zn and
Zn+Cu groups, respectively, and at home in 46.4%,
42.4% and 41.5%, respectively. This level of adherence
with the trial treatments corresponded to an average daily
intake of 14.3 mg of zinc in the Zn group, and 13.5 mg of
zinc and 1.3 mg copper in the Zn+Cu group over 14 days.
Effect of supplements on study outcomes
The mean duration of diarrhea from enrolment and the
mean stool weight during hospital stay were 63.7 hours
and 940 g, respectively, and there were no significant dif-
ferences in their adjusted means across trial groups (Table
3). Similarly, there were no differences in the adjusted
means of the amount of ORS or IV fluids used in the threeBMC Medicine 2009, 7:22 http://www.biomedcentral.com/1741-7015/7/22
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Flowchart Figure 1
Flowchart.
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groups. The median duration in hours (IQR) of diarrhea
in the Pl, Zn and Zn+Cu group was 48(48), 54(54) and
54(42), respectively. The proportion of patients with
diarrhea for more than 3 days was 26.7%, 27.8% and 27%
in the Pl, Zn and Zn+Cu groups, respectively. The propor-
tion of patients with diarrhea for more than 5 days was
4.9%, 7.3% and 7.4% in the Pl, Zn and Zn+Cu groups,
respectively. There was no significant difference in
diarrhea longer than 14 days. The observed reduction in
the point estimates of the severity of diarrhea indicated by
rates of complications, more than three episodes of some
dehydration or any episode of severe dehydration after
enrolment were not statistically significant (Table 3).
The Kaplan-Meier curves (Figure 2) for post-enrolment
duration of diarrhea showed there was no significant dif-
ference in cessation of diarrhea among the three groups
(log-rank test p = 0.6399). The RH of the Cox proportional
hazards model showed no significant reduction in the
duration of diarrhea in either Zn or Zn+Cu group after
adjusting for baseline covariates. Baseline serum zinc and
serum copper had no effect on the duration or volume of
diarrhea.
Effect of supplements on serum zinc and copper levels
At baseline the mean serum zinc concentration in the pla-
cebo group was significantly higher than the other treat-
ment groups and it had the least number of children with
levels under 60 μg/dl (Table 1). However, the increase in
zinc concentrations compared with baseline was signifi-
cantly (p < 0.001) greater in the supplemented groups as
compared with the placebo group (Table 3). The mean
percentage change in serum zinc from baseline was 17 ±
96, 28.9 ± 86.7 and 34.3 ± 107.7 in the Pl, Zn and Zn+Cu
groups, respectively. The mean serum copper at enrol-
ment was similar across treatment groups, and by the 14th
day the unadjusted increase in copper concentration was
significantly greater in the copper-supplemented group
compared with the Pl or Zn groups, and significantly
decreased from baseline in the Pl group.
Table 1: Comparison of baseline characteristics of the children by groups.
Placebo (N = 271) Zinc (N = 264) Zinc+Copper (N = 273)
Age [months, mean (SD)] 18.01 (11) 17.78 (11.6) 17.80 (10.8)
Age categories [N , (%)]
≤ 12 months 102 (37.6) 119 (45.1) 111 (40.7)
13 to 24 months 119 (43.9) 93 (35.2) 105 (38.5)
> 24 months 50 (18.5) 52 (19.7) 57 (20.9)
Male gender [N , (%)] 168 (62) 149 (56.4) 160 (58.6)
Mean number of children in family under 5 years 1.61 (0.8) 1.73 (0.8) 1.72 (0.8)
Mother's education [schooling years, mean (SD)] 6.72 (4.3) 7.46 (4.1) 6.70 (4.3)
Immunization complete to date [N , (%)] 178 (65.7) 190 (72) 181 (66.3)
Any breastfeeding [N , (%)] 161 (59.1) 142 (53.8) 150 (55)
Duration of illness (hours) 39.41 (22.2) 42.57 (26.9) 42.98 (27.7)
Duration of diarrhea (hours) 35.03 (20.5) 35.80 (20.6) 35.28 (20.3)
Duration of vomiting (hours) 20.92 (21) 20.19 (21.4) 19.93 (19.9)
Duration of fever (hours) 23.96 (24.2) 25.39 (26.3) 24.75 (29)
Dehydration status [N , (%)]
None 200 (73.8) 202 (76.5) 232 (85)
Some 67 (24.7) 57 (21.6) 32 (11.7)
Severe 4 (1.5) 5 (1.9) 9 (3.3)
Dysentery [N , (%)] 19 (7.0) 27 (10.0) 32 (11.7)
Received ORS [N , (%)] 122 (45.0) 129 (48.9) 104 (38.1)
Received any other medications [N , (%)] 127 (46.9) 122 (46.2) 116 (42.4)
Weight-for-age Z -score [mean (SD)] -2.14 (1.2) -2.07 (1.2) -2.17 (1.2)
Weight-for-age Z -score < -2 [N , (%)] 148 (54.6) 133 (50.4) 142 (52)
Weight-for-height Z -score < -2 [N , (%)] 145 (53.5) 138 (52.3) 148 (54.2)
Height-for-age Z -score < -2 [N , (%)] 91 (33.6) 78 (29.6) 96 (35.2)
Household wealth index [mean (SD)] 0.01 (1.1) 0.07 (1) --0.08 (0.9)
Water safety score [mean (SD)] 1.78 (0.9) 1.74 (0.9) 1.90 (1)
Hand washing score [mean (SD)] 1.24 (1) 1.20 (1) 1.25 (1.1)
Serum zinc [μg/dl, mean (SD)] 76.1 (30.2) 71.4 (37.9) 66.1 (28.2)
Serum zinc ≤ 60 μg/dl [N , (%)] 86 (31.7) 116 (43.9) 135 (49.5)
Serum Copper [μg/dl, mean (SD)] 122.4 (34.4) 124.3 (39.7) 123.9 (34.8)
Hemoglobin % [g/dl, mean (SD)] 9.60 (1.9) 9.89 (1.7) 9.55 (1.9)BMC Medicine 2009, 7:22 http://www.biomedcentral.com/1741-7015/7/22
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Discussion
The duration of diarrhea and the total stool output during
an episode of acute diarrhea were not significantly differ-
ent in the supplemented and placebo groups. Other out-
come measures such as the use of ORS, IV fluids, episodes
of dehydration experienced in the hospital, rates of com-
plications and diarrheal duration more than 7 days were
also no different in the children who received Zn or
Zn+Cu supplementation as compared with the placebo,
when adjusted for nutritional status, type of stool (pres-
ence or absence of dysentery) and baseline serum zinc or
copper levels. All children received similar doses, fre-
quency and duration of syrups of identical appearance for
14 days and the treatment adherence was similar in the
three groups. Serious adverse events related to the syrups
were not experienced by any child, suggesting that they
can be used safely in treatment protocols.
There could be many reasons for lack of effect observed in
our study. We first considered the possibility of either low
dose of zinc (an average intake per day of 13.9 mg over 14
days in any of the zinc groups) as compared with other
therapeutic studies that have used a fixed dose of 20 mg,
or poor treatment adherence, or failure of supplements to
replenish the zinc loss, as possible causes of the failure of
a favorable response to treatment. However, studies that
report administration of fixed dose of 20 mg have not
reported the actual mean consumption. Also, in our study
there was no difference in treatment adherence across the
three groups in the hospital stay or at home after discharge
(Table 2). The mean of absolute difference of serum zinc
from baseline to the 14th day increased significantly in
zinc-supplemented groups, indicating appropriate dose
and bioavailability of the supplements (Table 3).
It has been observed that there is a differential extent of
zinc deficiency, considered usually as serum zinc less than
60 μg/dl, across study populations, which could explain
the variation in effects of either prophylactic or therapeu-
tic zinc supplementation acute diarrhea [7]. It is expected
that those countries at high risk of zinc deficiency, that is,
prevalence stunting exceeding 20% and estimated preva-
lence of inadequate zinc intake of more than 25%, would
most likely benefit from prophylactic and therapeutic zinc
supplementation [18]. However, there is heterogeneity in
the effect of zinc during acute diarrhea even in those with
low plasma or serum zinc levels. Large studies from
Nepal, Zanzibar and India of prophylactic zinc supple-
mentation found no difference in morbidity and mortal-
ity of children aged 1 to 48 months between placebo and
supplemented groups [10,11,19]. However, a smaller pro-
phylactic study from Bangladesh did observe reduced
mortality in children, although the majority of the deaths
were pneumonia related [20]. The mean baseline plasma
zinc in these studies ranged from 62 to 78.7 μg/dl. A ther-
apeutic study from Bangladesh in infants also reported no
effect of zinc supplementation and the mean baseline zinc
of the study population was 68.5 μg/dl (see [7]).
Also, not all therapeutic studies that reported a beneficial
effect of zinc in acute diarrhea were in children with zinc
deficiency. Their serum or plasma zinc ranged from 58.0
Table 2: Percentage consumption of supplements by treatment group.
Percentage consumption* Intervention
Placebo Zinc Zinc+Copper
During stay in hospital (n (%))
0 to 50% 11 (4.1) 30 (11.4) 32 (11.7)
> 50 to 80% 45 (16.6) 59 (22.4) 69 (25.3)
> 80 to 100% 71 (26.2) 58 (22) 53 (19)
100 to 150% 95 (35.1) 77 (29.2) 80 (29.3)
> 150% 18 (6.6) 21 (7.95) 19 (6.96)
Total (mean ± sd) 108.6 ± 84 100.2 ± 68 94 ± 46
At home (n (%))
0 to 50% 47 (17.3) 63 (23.9) 68 (24.9)
> 50 to 80% 81 (29.9) 78 (29.5) 80 (29)
> 80 to 100% 56 (20.7) 36 (13.6) 43 (15.8)
100 to 150% 43 (15.9) 52 (19.7) 50 (18.3)
> 150% 12 (4.43) 16 (6.1) 12 (4.4)
Total (%, mean ± sd) 79.4 ± 37.7 78.6 ± 44 74.9 ± 40.9
Intake of zinc per day [mg, mean ± sd ] 14.3+6.9 13.5+5.1
*Percentage consumption = (amount of supplement consumed/amount of supplement prescribed) × 100BMC Medicine 2009, 7:22 http://www.biomedcentral.com/1741-7015/7/22
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Table 3: Study outcomes by intervention.
Outcome variable Intervention Mean ± sd Difference (95%CI)* Adjusted Difference (95%CI)**
Stool weight (g)
Placebo 876.9 ± 1194.1
Zn 972.3 ± 920.2 95.4 (-85.4,276.2) 21.1 (-40.8,83)
Zn+Cu 972.3 ± 1210 94.5 (-86.7,275.7) 23.8 (-35.5,83.1)
Duration of diarrhea (hours)a from enrollment
Placebo 62.2 ± 33.5
Zn 64.4 ± 37.8 2.2 (-4.1,8.5) 1.9 (-2.23,2.55)
Zn+Cu 64.4 ± 35 2.2 (-3.8,8.2) -0.9 (-2.37,2.2)
Amount of ORS used in hospital (ml)
Placebo 1666.5 ± 1372.7
Zn 1837.1 ± 1719.4 170.6 (-93.3,434.5) 42.8 (-45.6,131.2)
Zn+Cu 1811.9 ± 1499 145.4 (-96.7,387.5) 67.2 (-17.5,152.1)
Amount of IV fluids used in hospital (ml)
Placebo 127.3 ± 412.9
Zn 127.9 ± 358.2 0.7 (-65,66.4) 4.1 (-16,24.1)
Zn+Cu 131.7 ± 428 4.5 (-66.4,73.3) -1.2 (-20.7,18.3)
14th day zinc levels (μg/dL)
Pl 76.3 ± 32.9
Zn 76.6 ± 35. 0.3 (-5.8, 6.4) -1.1 (-3,0.9)
Zn+Cu 74.3 ± 40 -2 (-8.5, 4.6) -2.3 (-4.1,-0.5)
14th day copper levels (μg/dL)
Pl 115.2 ± 30.8
Zn 121.2 ± 35. 6.0 (0.1,11.9) 1.7 (-0.4,3.7)
Zn+Cu 124.6 ± 36.8 9.4 (3.4,15.5) 2.4 (0.5,4.3)
Mean absolute difference from baseline in Znc
Placebo 7.2 ± 379.6
Zn 59.2 ± 428.5 52 (-20.7,124.7) 34.8 (-11.7,81.2)
Zn+Cu 81.8 ± 452.8 74.5 (-0.11,149) 71.4 (30.9,111.9)
Mean absolute difference from baseline in Cud
Placebo -79.4 ± 429.2
Zinc -41.2 ± 418.8 38.2 (-37.8,114.3) 14 (-1.5,9.5)
Zn+Cu 15.6 ± 439.8 95 (39.3,17.7) 19.6 (3.6,35.6)
N (%) Odds ratio(95%CI) Adjusted odds ratio(95%CI)
Proportion with diarrhea of > 7 days from onsetb
Placebo 13(5.3)
Zn 20(8.1) 1.6 (0.77,3.25) 1.8 (0.78,3.97)
Zn+Cu 15(5.8) 1.11 (0.52,2.38) 1.18 (0.51,2.73)
N (%) IRR (95%CI)$ Adjusted IRR (95%CI)
Rates of complications in hospital
Placebo 14 (5.2)
Zn 10 (3.7) 0.73 (0.33,1.65) 0.76 (0.32,1.84)e
Zn+Cu 8 (2.9) 0.57 (0.24,1.35) 0.68 (0.26,1.78)
More than three episodes of some dehydration in hospital
Placebo 6 (2.2)
Zn 2 (0.8) 0.34 (0.07,1.7)e 0.35 (0.07,1.77)
Zn+Cu 5 (1.8) 0.83 (0.25,2.71) 0.94 (0.27,3.34)
Severe dehydration experience in hospital
Placebo 12 (4.4)
Zn 6 (2.3) 0.51 (0.19,1.37) 0.55 (0.21,1.49)
Zn+Cu 8 (2.9) 0.66 (0.27,1.62) 0.77 (0.31,1.94)
* The difference is as compared with the placebo group.
**Adjusted for following covariates: age, gender, prior duration of diarrhea, weight-for-age Z -score at most -2, dehydration status, receipt of 
medication, water safety, wealth index, type of stool, baseline serum zinc and serum copper.
$ Incidence rate ratios on Poisson regression. Beneficial effect is < 1.
aCensored duration of diarrhea: 16 in Zinc, 14 in Zinc/Copper treatment,24 in Placebo.
bCensored proportion with diarrhea > 7 days from onset: 16 in Zinc treatment, 14 in Zinc/Copper treatment, 24 in Placebo.
c Censored 14th day serum Zinc: 32 in Zinc treatment, 19 in Zinc/Copper treatment,21 in Placebo.
dCensored 14th day serum copper: 32 in Zinc treatment, 19 in Zinc/Copper treatment,21 in Placebo.BMC Medicine 2009, 7:22 http://www.biomedcentral.com/1741-7015/7/22
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to 92.9 μg/dl at baseline, with range of percentage change
at the end of the therapy being -1.7 to 42, thus failing to
establish a clear relation of response to zinc therapy and
underlying low blood zinc levels [10,19,21-26]. By com-
parison, in our study the mean baseline serum zinc level
was 71.2 μg/dl, with the highest proportion of children
with serum zinc at least 60 μg/dl in the Pl group. Although
the study outcomes were adjusted for baseline serum zinc
and copper, it is possible that there was a risk of longer
duration of diarrhea in the intervention groups as they
had lower baseline zinc. This may perhaps reduce the
observed difference in the diarrheal duration between
intervention and placebo groups. However, the overall
underweight rate in the study population (weight for age
less than -2 Z -score) was 52.4% and was balanced across
the groups. A limitation of this study, common to many
existing studies of therapeutic and prophylactic zinc sup-
plementation, is that serum zinc concentrations are not a
reliable measure of body zinc status [27]. Instead, meas-
urement of dietary zinc or copper intake and tissue zinc or
copper status could perhaps explain the differential
impact of zinc with respect to varying tissue zinc status.
Age can modify the beneficial effect of Zn supplementa-
tion. Two studies with infants younger than 6 months,
included in the Cochrane review, showed no impact of
zinc on duration of acute diarrhea. Although tissue zinc
status was not measured in these studies, they speculated
that perhaps the lack of effect was due to adequate zinc
stores acquired in utero , through breast feeding and lack
of preceding zinc depleting illness [7,28]. However, five
studies that included children aged 2 to 36 months (mean
age was 14.4 months), a large proportion of which were
also ever breast fed reported a beneficial effect [21,22,29-
31]. Thus, there is inconsistency in the evidence on
whether zinc stores in utero or those acquired from breast
feeding would diminish the impact of supplementation
on duration of acute diarrhea. In our study, 41% of the
children were between 6 and 12 months of age, the mean
age was 17.9 months and 56% had received any breast
feeding.
The impact of zinc supplementation may also be related
to different diarrheal etiology at different age groups and
study populations. Zinc has been postulated to have less
impact on rotavirus diarrhea and the secretory effect of
Escherichia coli heat-stable enterotoxin but beneficial
effects on enteropathogenic E. coli infection in animal
models [32-35]. The heterogeneity in effects of zinc for
acute childhood diarrhea could also be due to a varied
patient population, study designs (field based or hospital
based), the methods of monitoring diarrhea and the out-
The Kaplan-Meier curves for post enrolment duration of diarrhea in three groups Figure 2
The Kaplan-Meier curves for post enrolment duration of diarrhea in three groups.BMC Medicine 2009, 7:22 http://www.biomedcentral.com/1741-7015/7/22
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come measured. In a pooled analysis of three data sets, the
Zinc Investigators Collaborative Group in 1999 [36]
reported a multivariate RH of 0.85 (0.78, 0.92) or a 15%
lower probability for continuation of acute diarrhea in the
zinc group in studies from Indonesia (n = 1,368), India (n
= 931), and Bangladesh (n = 101). Although this contrasts
with our study, two of the three studies (Indonesia and
Bangladesh) showed no difference with RH (95% CI) for
continuation of diarrhea of 0.92 (0.83, 1.02) and 0.85
(0.57, 1.28), respectively. The pre-enrolment diarrheal
duration for Indonesia, India and Bangladesh was 1.9,
2.7, and 3.4 days respectively, and the mean post-enrol-
ment diarrheal duration was 3.5, 5.1 and 4.5 days, respec-
tively. Only the Indian study showed a mean difference of
1 day from placebo with an effect size of 0.24 (95% CI
0.10, 0.37) in the duration of diarrhea. Further, the Indian
and Indonesian studies were community-based trials
where cessation of diarrhea was defined as a 48-hour
period free of diarrhea (three to four unformed stools in
one day) measured from a 5 to 7 day recall of the mother.
The Bangladesh trial was a hospital-based study which
recruited children with diarrhea for less than 72 hours,
monitored 8-hourly in the hospitals for stool output and
cessation of diarrhea defined as passage of a soft formed
stool. These different study designs indicate that separate
meta-analyses for hospital-monitored and community-
based studies are required to fully assess the therapeutic
effects of zinc in acute diarrhea.
Finally, in several studies it is difficult to ignore the inter-
actions of zinc with multivitamins or co-interventions
administered to the study populations. The Zinc Investi-
gators Collaborative Group further conducted a meta-
analysis of three of the above mentioned studies and two
additional studies [25,37] from India and Bangladesh.
Since multivitamins including vitamin A were adminis-
tered with zinc in three studies, a potentially beneficial
interaction of zinc with vitamin A or other vitamins can-
not be ruled out. Zinc is involved in the release of vitamin
A from liver cells and in the synthesis of retinol binding
protein, and the effect of zinc in infectious diseases may
be dependent on an adequate vitamin A status [38-40].
Moreover, there are no studies directly examining the rela-
tionship between the different B vitamins and diarrheal
disease, which makes it difficult to arrive at any conclu-
sions about their effects on this outcome [30]. It is also
noteworthy that blinding is a challenge when combina-
tions of drugs are used. In one of the Indian studies
included in a recent meta-analysis, glucose water was used
as a placebo which is neither identical in appearance or
taste to the intervention, making the double blinding
questionable [25].
This trial is the first to evaluate the impact of oral zinc and
copper administration on duration of acute diarrhea,
serum zinc and copper levels after 14 days of supplemen-
tation. Large oral doses and a relatively low dose of dietary
zinc are known to interfere with copper bioavailability
[41], and contrarily, copper may interfere with zinc
absorption and obliterate its effect [42]. A diarrheal mor-
bidity trial of 4 months zinc supplementation in north
Indian children reported a significantly lower copper level
in the zinc supplemented group, and an adverse effect on
copper levels at the end of the study [43]. However, we
supplemented zinc and copper in the same ratio as in a
customary diet and therefore this Zn-Cu interaction
would be unlikely [44,45]. Also, a significant fall in serum
copper levels from baseline was observed only in the pla-
cebo group, which had no effect on diarrheal duration.
Similar results have been observed in other studies
[11,20,21].
Conclusion
The results of our study further highlight the heterogene-
ity of results of zinc supplementation in acute diarrhea.
Thus, it appears that therapeutic Zn supplementation may
not have a universal beneficial impact on the duration of
acute diarrhea. A re-examination of all available trial
results, including this trial, is needed to dissect out the
potential contributors to heterogeneity of trial results
before Zn can be universally recommended for treatment
of acute childhood diarrhea.
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